Targeting EIF3FP2: A Promising Approach To Cancer Treatment (G83880)

Target Name: EIF3FP2

NCBI ID: G83880

EIF3FP2

Other Name(s): eukaryotic translation initiation factor 3 subunit F pseudogene 2 | Eukaryotic translation initiation factor 3, subunit F pseudogene 2 | IFP38

Targeting EIF3FP2: A Promising Approach To Cancer Treatment

EIF3FP2, also known as eukaryotic translation initiation factor 3 subunit F pseudogene 2, is a protein that plays a critical role in the process of translation of RNA into protein in eukaryotic cells. It is a key regulator of the initiation of the translation process, and its function is to ensure that the correct sequence of RNA is translated into the correct protein.

Mutations in the EIF3FP2 gene have been linked to a variety of genetic disorders, including splicing disorders, neurodegenerative diseases, and developmental disorders. Additionally, over-expression of EIF3FP2 has been shown to promote the growth and survival of cancer cells.

Due to its role in translation, EIF3FP2 has been identified as a potential drug target. By inhibiting the activity of EIF3FP2, researchers have found that they can reduce the amount of protein produced by cancer cells, leading to a decrease in cell growth and a slowing in the progression of cancer.

One strategy for targeting EIF3FP2 is to use small molecules, such as drugs that inhibit the activity of the protein. Researchers have identified a number of small molecules that have been shown to inhibit the activity of EIF3FP2, and are currently in the process of testing these compounds for use as potential drugs.

Another approach to targeting EIF3FP2 is to use antibodies that specifically recognize and target the protein. Researchers have developed antibodies that are designed to bind to EIF3FP2 and are currently being tested for use in clinical trials.

While the use of small molecules and antibodies to target EIF3FP2 is still in the early stages of research, it holds great promise as a potential drug. By inhibiting the activity of this protein, researchers hope to reduce the amount of protein produced by cancer cells and slow the progression of cancer.

EIF3FP2 is also a potential biomarker for cancer. Its over-expression has been associated with the development of a number of cancer types, including breast, ovarian, and prostate cancer. By using antibodies or small molecules to target EIF3FP2, researchers hope to be able to detect and treat cancer at an early stage, when it is most treatable.

In conclusion, EIF3FP2 is a protein that plays a critical role in the process of translation of RNA into protein in eukaryotic cells. Its function is to ensure that the correct sequence of RNA is translated into the correct protein, and mutations in the EIF3FP2 gene have been linked to a variety of genetic disorders. Additionally, over-expression of EIF3FP2 has been shown to promote the growth and survival of cancer cells, making it a potential drug target and a potential biomarker for cancer. While the use of small molecules and antibodies to target EIF3FP2 is still in the early stages of research, it holds great promise as a potential drug, and its potential as a biomarker for cancer is also exciting.

Protein Name: Eukaryotic Translation Initiation Factor 3 Subunit F Pseudogene 2

The "EIF3FP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF3FP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets